GlassScriptPhysician profile
Ashley A Rohr
NPI 1629364708
$2,854.87
in general payments reported to CMS, 2019-2025
20 companies · $569 in 2025
The $569 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.69 · 2021: $85.02 · 2022: $427 · 2023: $252 · 2024: $1,469 · 2025: $569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,530 · Travel and Lodging: $760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,529.75 |
| Travel and Lodging | $760.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,291.75 | 2019-2024 | Clareon, Hydrus Microstent |
| Glaukos Corporation | $449.68 | 2022-2025 | Idosetr, Idose |
| Sight Sciences, INC. | $291.18 | 2021-2023 | Omni Surgical System |
| Biotissue Holdings INC. | $193.29 | 2023-2025 | |
| Eyevance Pharmaceuticals LLC | $158.80 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $116.51 | 2019-2025 | |
| Harrow Eye, LLC | $49.56 | 2024-2025 | Vevye |
| Amgen INC. | $46.45 | 2025 | Tepezza |
| Bausch & Lomb Americas INC. | $38.53 | 2024-2025 | Vyzulta, Miebo, Xiidra |
| Dompe US, INC. | $29.60 | 2025 | Oxervate |
| Beaver-Visitec International, INC. | $24.53 | 2025 | |
| Tearlab Corp | $22.62 | 2024 | Scoutpro Osmolarity System |
| Shire North American Group INC | $22.29 | 2019 | |
| Thea Pharma INC. | $21.99 | 2023 | Iyuzeh |
| Mallinckrodt Hospital Products INC. | $20.38 | 2025 | Acthar |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $19.67 | 2024 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $18.29 | 2025 | Xdemvy |
| Astellas Pharma US INC | $13.33 | 2024 | Izervay |
| Abbvie INC. | $13.25 | 2023 | Lumigan, Vuity, Alphagan P |
| Allergan, INC. | $13.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Rohr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.